| scholarly article | Q13442814 |
| P2093 | author name string | Yi-Chien Lee | |
| Aykut Uren | |||
| Jeffrey A Toretsky | |||
| Metin Ozdemirli | |||
| Michael D Hall | |||
| Olga Rodriguez | |||
| Gülay Bulut | |||
| Elspeth M Beauchamp | |||
| Tobey J Macdonald | |||
| Chris Albanese | |||
| Daniel Peaceman | |||
| Kamal P Sajwan | |||
| Lymor Ringer | |||
| P2860 | cites work | Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma | Q24303922 |
| Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome | Q24336457 | ||
| The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase | Q24561826 | ||
| Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector | Q24631549 | ||
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 | ||
| Vertebrate Smoothened functions at the primary cilium | Q27919682 | ||
| Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1 | Q28215795 | ||
| Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system | Q28270384 | ||
| Specific covalent labeling of recombinant protein molecules inside live cells | Q28276029 | ||
| Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide | Q28277241 | ||
| Identification of an amplified, highly expressed gene in a human glioma | Q28300727 | ||
| A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia | Q28387697 | ||
| Mouse intraflagellar transport proteins regulate both the activator and repressor functions of Gli transcription factors | Q28509134 | ||
| Hedgehog signaling and primary cilia are required for the formation of adult neural stem cells | Q28512856 | ||
| Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation | Q28586404 | ||
| Hedgehog signalling in the mouse requires intraflagellar transport proteins | Q28593010 | ||
| Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli | Q28593401 | ||
| Patched1 regulates hedgehog signaling at the primary cilium | Q29547515 | ||
| Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia | Q33178068 | ||
| Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide | Q33291299 | ||
| GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors | Q33512928 | ||
| Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. | Q33551142 | ||
| Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors | Q33699094 | ||
| Primary cilia are required for cerebellar development and Shh-dependent expansion of progenitor pool | Q33705922 | ||
| Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. | Q33754614 | ||
| Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis | Q33954530 | ||
| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma | Q34019208 | ||
| Mutations in SUFU predispose to medulloblastoma | Q34133729 | ||
| History of the development of arsenic derivatives in cancer therapy | Q34514920 | ||
| Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma | Q34584174 | ||
| Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). | Q35098057 | ||
| Arsenic in drinking-water and risk for cancer in Denmark | Q36448664 | ||
| REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma | Q36987393 | ||
| GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. | Q37152828 | ||
| Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. | Q38444043 | ||
| Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. | Q39684126 | ||
| BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing's sarcoma family of tumours | Q39983431 | ||
| The EWS/FLI1 oncogenic transcription factor deregulates GLI1. | Q40034798 | ||
| Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas | Q40145800 | ||
| Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro | Q40240010 | ||
| Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. | Q40285122 | ||
| Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells | Q40286206 | ||
| The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas | Q40497319 | ||
| Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site | Q40566346 | ||
| Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase | Q40857729 | ||
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 | ||
| Recombinant EWS-FLI1 oncoprotein activates transcription | Q42043409 | ||
| Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. | Q42439709 | ||
| Gli1 is important for medulloblastoma formation in Ptc1+/- mice | Q42476399 | ||
| Myocardial toxicity of arsenic trioxide in a mouse model | Q44110118 | ||
| Medulloblastoma growth inhibition by hedgehog pathway blockade | Q44119270 | ||
| Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. | Q44255817 | ||
| Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation | Q46388996 | ||
| Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling | Q46660701 | ||
| Interaction of trivalent arsenicals with metallothionein | Q47750402 | ||
| The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. | Q53492300 | ||
| Amplification of the gli gene in childhood sarcomas. | Q55485055 | ||
| BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity | Q58414471 | ||
| Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice | Q73555767 | ||
| Differential expression of Sonic hedgehog and Gli1 in hematological malignancies | Q81422102 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arsenic | Q871 |
| arsenic trioxide | Q7739 | ||
| cell growth | Q189159 | ||
| P304 | page(s) | 148-60 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway | |
| P478 | volume | 121 |
| Q52646455 | A highlight on Sonic hedgehog pathway. |
| Q47823690 | A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors |
| Q36866043 | A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood |
| Q48215997 | A synthetic combinatorial approach to disabling deviant Hedgehog signaling |
| Q40483871 | Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy |
| Q48116800 | Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. |
| Q37990470 | Anticancer drugs from traditional toxic Chinese medicines |
| Q37565093 | Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer |
| Q47136308 | Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications |
| Q36502959 | Arsenic Attenuates GLI Signaling, Increasing or Decreasing its Transcriptional Program in a Context-Dependent Manner. |
| Q64120142 | Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling |
| Q64101518 | Arsenic Trioxide and (-)-Gossypol Synergistically Target Glioma Stem-Like Cells via Inhibition of Hedgehog and Notch Signaling |
| Q93163558 | Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup |
| Q38935233 | Arsenic inhibits hedgehog signaling during P19 cell differentiation |
| Q90707336 | Arsenic trioxide and curcumin attenuate cisplatin-induced renal fibrosis in rats through targeting Hedgehog signaling |
| Q28481142 | Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6 |
| Q36841351 | Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer |
| Q38921254 | Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy |
| Q99582835 | Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell-maintenance factors and inducing apoptosis via the Hedgehog signaling blockade |
| Q53073070 | Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. |
| Q37120649 | Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli |
| Q28534552 | Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation |
| Q34429067 | Arsenic: a potentially useful poison for Hedgehog-driven cancers |
| Q27006913 | Basal cell carcinoma - molecular biology and potential new therapies |
| Q38593322 | Basal cell naevus syndrome: an update on genetics and treatment |
| Q91729476 | Bicyclic imidazolium inhibitors of Gli transcription factor activity |
| Q55462417 | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. |
| Q35894540 | Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy |
| Q41923624 | Bone sarcomas: from biology to targeted therapies. |
| Q93079163 | Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor |
| Q49334989 | Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells |
| Q38389719 | Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. |
| Q33798299 | Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model |
| Q27027214 | Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy |
| Q26865136 | Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy |
| Q98177125 | Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination |
| Q36277354 | Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo |
| Q28833786 | DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance |
| Q27312382 | Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling |
| Q39185473 | Development of anticancer agents targeting the Hedgehog signaling |
| Q38945222 | Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors |
| Q96954691 | Discovery of Small Molecule Inhibitors Targeting the Sonic Hedgehog |
| Q41716968 | Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth |
| Q38563638 | EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. |
| Q40566977 | Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model |
| Q38908981 | Emerging from their burrow: Hedgehog pathway inhibitors for cancer |
| Q100490624 | Emerging role of tumor cell plasticity in modifying therapeutic response |
| Q36728942 | Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. |
| Q38652681 | Evolving molecular era of childhood medulloblastoma: time to revisit therapy |
| Q37981253 | Ewing sarcoma: biology-based therapeutic perspectives |
| Q91644156 | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| Q36819689 | From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network |
| Q38969673 | GLI2 is a novel therapeutic target for metastasis of osteosarcoma |
| Q27852966 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition |
| Q91639231 | Ginsenoside Rh2 activates α-catenin phosphorylation to inhibit lung cancer cell proliferation and invasion |
| Q34981146 | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. |
| Q59330240 | Gα signaling controls intramembranous ossification during cranial bone development by regulating both Hedgehog and Wnt/β-catenin signaling |
| Q58800972 | Hedgehog Signaling Pathway and Autophagy in Cancer |
| Q26799894 | Hedgehog Signaling in Malignant Pleural Mesothelioma |
| Q39175185 | Hedgehog Signaling: From Basic Biology to Cancer Therapy |
| Q35885181 | Hedgehog pathway as a drug target: Smoothened inhibitors in development |
| Q37694614 | Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression |
| Q38072095 | Hedgehog pathway inhibitors: a patent review (2009--present). |
| Q38863974 | Hedgehog signaling contributes to basic fibroblast growth factor-regulated fibroblast migration |
| Q26992348 | Hedgehog signaling inhibitors as anti-cancer agents in osteosarcoma |
| Q38100713 | Hedgehog signaling pathway and cancer therapeutics: progress to date |
| Q37551492 | Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas |
| Q35602348 | Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. |
| Q92263331 | Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications |
| Q35740170 | High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases |
| Q30488315 | Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box. |
| Q38665997 | Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1. |
| Q38902471 | Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma |
| Q57462062 | Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses |
| Q45040163 | Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma |
| Q55022167 | Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. |
| Q28076101 | In vitro models of cancer stem cells and clinical applications |
| Q54550236 | Inhibition of hedgehog signaling induces monocytic differentiation of HL-60 cells. |
| Q35142436 | Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses |
| Q24632161 | Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists |
| Q35832266 | Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization |
| Q61446372 | MEP50/PRMT5-mediated methylation activates GLI1 in Hedgehog signalling through inhibition of ubiquitination by the ITCH/NUMB complex |
| Q30847947 | Management of pediatric and adult patients with medulloblastoma |
| Q40022752 | Manganese-Enhanced Magnetic Resonance Imaging as a Diagnostic and Dispositional Tool after Mild-Moderate Blast Traumatic Brain Injury |
| Q37982341 | Matching mice to malignancy: molecular subgroups and models of medulloblastoma |
| Q42002403 | Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications |
| Q38003345 | Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors |
| Q86229571 | Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression |
| Q38104413 | New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies |
| Q64912138 | Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. |
| Q64992804 | Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened. |
| Q36168155 | Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth |
| Q47144270 | Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma |
| Q34021681 | Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors |
| Q38113988 | Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy |
| Q21129295 | Pediatric medulloblastoma - update on molecular classification driving targeted therapies |
| Q49511494 | Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy |
| Q36040432 | Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis |
| Q28072744 | Potential approaches to the treatment of Ewing's sarcoma |
| Q34503415 | Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. |
| Q36392140 | Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. |
| Q91614261 | Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer |
| Q38213666 | Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies |
| Q57962903 | Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer |
| Q38121136 | Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy |
| Q58692807 | Role of GLI Transcription Factors in Pathogenesis and Their Potential as New Therapeutic Targets |
| Q92757280 | Role of Protein Kinases in Hedgehog Pathway Control and Implications for Cancer Therapy |
| Q89944036 | SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression |
| Q38649653 | Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions |
| Q37690128 | Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. |
| Q92419809 | Silencing of the MEKK2/MEKK3 Pathway Protects against Spinal Cord Injury via the Hedgehog Pathway and the JNK Pathway |
| Q38039960 | Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer |
| Q28483716 | Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells |
| Q38740268 | Solasonine, A Natural Glycoalkaloid Compound, Inhibits Gli-Mediated Transcriptional Activity. |
| Q38244794 | Sonic hedgehog signaling in Basal cell nevus syndrome |
| Q92393288 | Sonic hedgehog signaling in epithelial tissue development |
| Q54978026 | Sonic hedgehog-c-Jun N-terminal kinase-zinc finger protein Gli1 signaling protects against high glucose concentration-induced reactive oxygen species generation in human fibroblasts. |
| Q47218042 | Strategies to target the Hedgehog signaling pathway for cancer therapy. |
| Q28271278 | Survival regulation of leukemia stem cells |
| Q39281476 | Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma |
| Q38178277 | Targeted therapies for bone sarcomas |
| Q37981129 | Targeted therapy in bone and soft tissue sarcoma in children and adolescents |
| Q38222028 | Targeted treatment for sonic hedgehog-dependent medulloblastoma. |
| Q92512238 | Targeting cancer stem cells in drug discovery: Current state and future perspectives |
| Q89185752 | Targeting mTOR as a Therapeutic Approach in Medulloblastoma |
| Q91620717 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update |
| Q36900021 | Targeting sonic hedgehog signaling by compounds and derivatives from natural products |
| Q60954611 | Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors |
| Q26764892 | Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors |
| Q37269236 | Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. |
| Q92503087 | The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer? |
| Q36902958 | The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy |
| Q37879912 | The Hedgehog's tale: developing strategies for targeting cancer |
| Q26740373 | The hedgehog pathway in triple-negative breast cancer |
| Q35109835 | The hedgehog/Gli signaling paradigm in prostate cancer |
| Q39036566 | The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma |
| Q38031211 | The utility of hedgehog signaling pathway inhibition for cancer |
| Q38160739 | Unraveling the therapeutic potential of the Hedgehog pathway in cancer |
| Q30514653 | VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells |
Search more.